Swedish Orphan Biovitrum AB (publ) (STO:SOBI)
Sweden
· Delayed Price · Currency is SEK 375.80
-0.80 (-0.21%)
At close: Mar 9, 2026
STO:SOBI Revenue
In the year 2025, Swedish Orphan Biovitrum AB had annual revenue of 28.24B SEK with 8.50% growth. Swedish Orphan Biovitrum AB had revenue of 7.82B in the quarter ending December 31, 2025, with 5.19% growth.
Revenue
28.24B
Revenue Growth
+8.50%
P/S Ratio
4.60
Revenue / Employee
14.96M
Employees
1,888
Market Cap
129.90B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 28.24B | 2.21B | 8.50% |
| Dec 31, 2024 | 26.03B | 3.90B | 17.65% |
| Dec 31, 2023 | 22.12B | 3.33B | 17.74% |
| Dec 31, 2022 | 18.79B | 3.26B | 21.00% |
| Dec 31, 2021 | 15.53B | 268.00M | 1.76% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioGaia AB | 1.54B |
| Cereno Scientific AB | 44.27M |
| EQL Pharma AB | 425.75M |
| Orexo AB | 26.00M |
| Cinclus Pharma Holding AB | 57.47M |
| Nanexa AB | 55.94M |
| Dicot Pharma AB | 200.00K |
| Enzymatica AB | 53.90M |
Swedish Orphan Biovitrum AB News
- 6 months ago - 10 stocks to consider if you want alternatives to the expensive S&P 500 - Market Watch
- 1 year ago - Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ) - PRNewsWire
- 1 year ago - Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ) - PRNewsWire
- 2 years ago - Change in number of shares and votes in Swedish Orphan Biovitrum AB (publ) - PRNewsWire
- 2 years ago - Bulletin from Swedish Orphan Biovitrum (Sobi)'s Extraordinary General Meeting (EGM) - PRNewsWire
- 2 years ago - New number of shares and votes in Swedish Orphan Biovitrum AB (publ) - PRNewsWire
- 2 years ago - Swedish Orphan Biovitrum AB: Late-breaking efanesoctocog alfa data presented at ISTH demonstrates highly effective bleed protection in children with severe haemophilia A with once-weekly dosing - PRNewsWire
- 3 years ago - CTI BioPharma Soars After Agreeing $1.7 Billion Sale. Biotech Deals Keep Coming. - Barrons